Joshua Chalkley, DO
Neurology · Lexington, KYNPI 1043368491
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,523 of the $15,289 with a category attached, or 75.4%. Biogen accounts for 79.2% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2023 at $13,181 and has fallen 98.9% since, to $141 in 2025.
Across 152 payments — averaging $100.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$12K
- AstraZeneca$1K
- Novartis$400
- TG Therapeutics, Inc.$255
- Abbott$225
- AbbVie$169
- plus $932 from 19 others
What the payments were for
- Consulting fees$1251%
- Speaking & faculty fees$11,52375%
- Food & beverage$2,86819%
- Education$7725%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 26 | $12,114 |
| AstraZeneca | 20 | $1,193 |
| Novartis | 21 | $400 |
| TG Therapeutics, Inc. | 9 | $255 |
| Abbott | 4 | $225 |
| AbbVie | 17 | $169 |
| EMD Serono, Inc. | 10 | $152 |
| Genentech USA, Inc. | 8 | $131 |
| Sanofi | 4 | $71 |
| Argenx US, Inc. | 3 | $64 |
| Lilly USA, LLC | 4 | $60 |
| Mallinckrodt Enterprises LLC | 2 | $54 |
| Integra Lifesciences Corporation | 2 | $54 |
| UCB, Inc. | 2 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Pfizer | 3 | $48 |
| Sumitomo Pharma America, Inc. | 5 | $38 |
| Neurelis, Inc. | 2 | $32 |
| Boston Scientific | 1 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Atricure, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Livanova USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,289 in reported general payments places this provider in the 75th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 127 | $1,178,674 |
| MayzentSiponimod | 45 | $418,239 |
| EnspryngSatralizumab-Mwge | 19 | $306,624 |
| VumerityDiroximel Fumarate | 19 | $153,864 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $106,084 |
| CopaxoneGlatiramer Acetate | 19 | $98,080 |
| Dalfampridine ErDalfampridine | 136 | $74,431 |
| Nurtec OdtRimegepant Sulfate | 41 | $43,744 |
| Mycophenolate Mofetil | 72 | $26,085 |
| UbrelvyUbrogepant | 22 | $23,433 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $19,887 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $19,271 |
| QuliptaAtogepant | 11 | $12,233 |
| LyricaPregabalin | 16 | $9,768 |
| Teriflunomide | 17 | $4,390 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisMayzent | $400 | $418,23945 claims |
| Genentech USA, Inc.Enspryng | $131 | $306,62419 claims |
| BiogenVumerity | $12,114 | $153,86419 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $50 | $98,08019 claims |
| PfizerNurtec Odt, Lyrica | $48 | $53,51257 claims |
| AbbVieUbrelvy, Qulipta | $169 | $35,66633 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $21 | $19,88712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 210 neurology providers in Kentucky.
Other neurology in Lexington
- James WinkleyLexington$807K
- Nicole EvermanLexington$355K
- Toufic FakhouryLexington$278K
- Fred OdagoLexington$28K
- Zabeen MahuwalaLexington$28K
- Jagannadha AvasaralaLexington$15K
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Naveed AhmedPikeville$215K
- Angela HardwickLouisville$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.